Music Licensing Inc (SONG): He'll never learn, he is going to jail.

Play Episode

3min

Proactive - Interviews for investors

Quantum Base to list on AIM with £5M IPO plan

Quantum Base CEO Tom Taylor joined Stephen Gunnion in the Proactive studio with more about the company’s upcoming listing on the AIM market and its breakthrough anti-counterfeiting technology. Quantum Base, founded in 2013 as a spin-out from Lancaster University, has developed an atomic fingerprint that offers 100% secure authentication of goods, scannable with any smartphone. “It tells you 100% if something is real or it's fake,” Taylor said, describing the technology as a major leap in the fight against counterfeiting. Taylor explained that the technology has applications across sectors including brand protection, pharmaceuticals, tax stamps, banknotes, passports and even aerospace parts. The firm is already working with clients globally—from North America to the Middle East—and targeting both commercial brands and government organisations. The IPO is expected to raise £5 million, with £4.70 million already committed and trading set to begin on Friday under the ticker QUBE. The retail offer remains open. “We really want to grow… AIM really helps us grow,” Taylor said, noting the listing will support product development and expansion into new verticals. Key uses of the funds will include expanding Quantum Base’s commercial team and scaling its product reach into global markets. Looking ahead, Taylor said investors should watch for announcements of new customers and entry into new industries as milestones on the path to profitability. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #QuantumBase #TomTaylor #AntiCounterfeiting #AtomicFingerprint #AIMListing #IPO2025 #SmartphoneSecurity #PharmaceuticalSecurity #BrandProtection #QuantumTech #QUBE #InvestmentNews #ProactiveInvestors

Proactive - Interviews for investors

Time Finance CEO on Q3 update: record lending & growth to resilient small businesses

Time Finance PLC (AIM:TIME) CEO Ed Rimmer takes Proactive's Stephen Gunnion through the company’s performance in the third quarter, highlighting a record gross lending book and improved arrears management. Rimmer explained that Time Finance provides funding solutions to small businesses, including invoice finance, asset finance, and secured loans, typically supporting businesses with turnover up to £10 million. He said, “We help businesses grow, but we also help businesses to survive as well.” The company’s lending book reached a record £210 million at the end of February, with arrears falling to 5% from 6% a year earlier. Rimmer noted this progress came despite challenging market conditions and was achieved without compromising credit quality. Margins have also increased, with profit margins now at 40%. This was attributed to tight cost control and improved efficiency, including leveraging technology and streamlining internal processes. Time Finance has not increased its headcount significantly post-COVID, which has helped support margin growth. Rimmer also addressed the broader economic environment, pointing to interest rate pressures, inflation, and increased insolvencies, but emphasised that small businesses remain resilient. The company sees opportunity as traditional banks become more risk-averse, creating space for independent lenders. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #TimeFinance #SMElending #AlternativeFinance #BusinessLoans #InvoiceFinance #AssetFinance #Q3TradingUpdate #IndependentLender #FinancialResults #SmallBusinessFinance

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Abacus Global Management CEO on 2024 highlights and 2025 targets

Abacus Global Management (NASDAQ:ABL) CEO Jay Jackson takes Proactive's Stephen Gunnion through the company’s strong financial performance in 2024 and its strategic outlook for 2025. The pioneering alternative asset manager reported 69% year-over-year revenue growth for 2024, with the fourth quarter alone seeing a 40% increase. Jackson noted that 2023 was already a record year, and 2024 surpassed that benchmark by over 50%. The company has issued guidance for 2025 that anticipates adjusted net income to rise by between 51% and 68%, driven by continued demand for non-correlated assets. Founded over 20 years ago, Abacus recently rebranded from Abacus Life to better reflect its identity as an alternative asset manager. Jackson explained, “We're an asset manager... and we also own a large institutional asset manager in Luxembourg,” underlining the firm’s expanding global footprint. Growth drivers include strategic acquisitions, expansion of its financial advisor channel, and development in its technology division. Jackson emphasized the role of AI in analyzing health and lifespan data to support financial planning, stating, “Think about the billion scenarios in someone's lifespan… AI helps us understand more accurate outcomes.” Jackson believes 2025 will bring increasing attention to the firm’s asset management operations, complementing its origination and technology capabilities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #AbacusGlobal #AlternativeAssets #JayJackson #AssetManagement #LifeInsuranceInvesting #AIinFinance #FinancialPlanning #SmallCapStocks #2025Outlook #InvestorInsights #NonCorrelatedAssets #TechInFinance

Followers	6
Posts	1417
Boards Moderated	0
Alias Born	07/27/2023

Volume:	899
Day Range:	10.00 - 10.00
Bid:	3.50
Ask:	15.00
Last Trade Time:	12:41:11 PM EDT
Total Trades:	13

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SONG Detailed Quote

Recent SONG News

More SONG News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent SONG News

Go Ad-Free